Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Rodding and pinning in hypophosphatasia (HPP) demand specialized orthopedic protocols because the underlying bone chemistry, not just bone shape, drives failure. In HPP, deficient tissue-nonspecific alkaline phosphatase allows inorganic pyrophosphate to accumulate, blocking mineralization so bone remains soft, poorly healing, and prone to pseudofractures that standard fixation cannot resolve. Hardware placed in undermineralized bone tends to loosen, migrate, or cut out, and nonunion rates are high, which is why load-sharing intramedullary rods are generally favored over rigid plates and why implant selection, thread placement, and timing must account for delayed callus formation. Metabolic optimization matters as much as mechanics, including enzyme replacement therapy considerations, vitamin B6 monitoring, and avoiding bisphosphonates, which can worsen mineralization suppression. There are several important factors and surgical planning details to consider, so see below to understand more.
Because bone pain, recurrent stress fractures, dental loss, and muscle weakness can look like many other conditions, understanding your own pattern of symptoms is a useful first step before surgical decisions are made. A free, instant, online symptom check can help you organize what you are experiencing, see which possibilities align with your history, and prepare clearer questions for your orthopedic or metabolic bone specialist so next steps are not delayed.
Last reviewed for medical accuracy: 08/18/2026
Hypophosphatasia (HPP) is a rare metabolic bone disorder characterized by low alkaline phosphatase activity, resulting in soft, fragile bones and impaired fracture healing. In adults with HPP, orthopedic interventions such as rodding and pinning carry higher risks than in the general population. Understanding orthopedic surgery precautions in adult HPP helps patients and clinicians plan safer, more effective care.
Rodding and pinning are surgical techniques used to stabilize fractures or deformities:
In HPP, compromised bone mineralization and healing capacity make these procedures complex. Without tailored protocols, patients face risks such as rod migration, nonunion (pseudarthrosis), secondary fractures, infection, and prolonged immobilization.
Bone Fragility
• HPP bones are softer and more brittle.
• Standard reaming or forceful instrumentation can cause additional microfractures or bone splintering.
Impaired Healing
• Hypophosphatasia slows callus formation and mineralization.
• Traditional fixation timelines may be inadequate, leading to delayed unions or nonunions.
Variable Disease Severity
• Adult HPP ranges from mild stress fractures to severe, recurrent pseudofractures.
• One-size-fits-all surgical plans fail to address individual biochemical and structural needs.
Enzyme Replacement Impact
• Asfotase alfa (recombinant alkaline phosphatase) can improve bone health but alters healing dynamics.
• Coordination between metabolic therapy and surgery timing is essential.
Before surgery, a detailed assessment guides risk reduction:
Multidisciplinary Team
• Involve metabolic specialists, endocrinologists, radiologists, and experienced orthopedic surgeons.
• Coordinate bone-targeted therapy (asfotase alfa) with surgical planning.
Biochemical Optimization
• Measure serum alkaline phosphatase, calcium, phosphate, vitamin D, and pyridoxal 5′-phosphate (PLP).
• Correct deficiencies; maintain vitamin D in the upper-normal range to support mineralization.
Imaging and Bone Quality Assessment
• High-resolution CT or MRI to evaluate cortical thickness and medullary canal size.
• Dual-energy X-ray absorptiometry (DXA) to track bone density trends.
Preoperative Patient Counseling
• Discuss prolonged healing timelines, risk of revision surgery, and realistic functional goals.
• Encourage tobacco cessation, optimal nutrition, and weight management to reduce surgical stress.
Tailoring the surgical approach minimizes complications:
Gentle Handling and Exposure
• Use minimally invasive techniques when feasible to preserve periosteal blood supply.
• Limit soft-tissue stripping to maintain healing capacity.
Rod and Pin Selection
• Choose flexible, smaller-diameter rods or pins to match the softened cortex.
• Avoid aggressive reaming—use drill bits below the rod’s final diameter.
Fixation Technique
• Consider elastic intramedullary nails or hydroxyapatite-coated implants to enhance purchase in poor bone.
• Use locking plates with multiple screws to distribute load and reduce stress concentration.
Intraoperative Monitoring
• Fluoroscopy to confirm accurate implant placement and detect unintended fractures.
• Neuromonitoring if deformity correction carries nerve injury risk.
Adjunctive Therapies
• Local application of bone morphogenetic proteins (BMPs) or demineralized bone matrix in high-risk nonunion areas.
• Administer low-dose perioperative antibiotics to prevent infection.
After surgery, careful follow-up supports healing:
Immobilization and Weight Bearing
• Tailor weight-bearing status—often partial or non-weight bearing for extended periods (8–12 weeks).
• Use custom bracing or casts to offload stress from the surgical site.
Physical Therapy
• Initiate gentle range-of-motion exercises to prevent joint stiffness without overloading bone.
• Gradually progress to muscle strengthening under close supervision.
Metabolic Monitoring
• Continue enzyme replacement (asfotase alfa) per metabolic specialist guidance.
• Repeat biochemical tests (ALP, calcium, phosphate) every 4–8 weeks.
Radiographic Surveillance
• X-rays at 4, 8, and 12 weeks post-op, then at 6-month intervals until complete union.
• Watch for signs of delayed union, implant loosening, or secondary fractures.
Pain and Complication Management
• Use multimodal analgesia—acetaminophen, NSAIDs (cautiously), and opioid sparing approaches.
• Promptly address any signs of infection, hardware failure, or neurovascular compromise.
Rodding and pinning in adults with HPP demand orthopedic surgery precautions in adult HPP that go beyond standard fracture care. By combining metabolic optimization, specialized surgical techniques, and vigilant postoperative monitoring, healthcare teams can reduce complications and promote stronger, more reliable bone healing. Always discuss any serious or life-threatening concerns with your doctor, and speak to a physician before making decisions about your health.
(References)
* Drees P, Schmidt D, Lewens T, Vetter T, Meurer A. [Hyperphosphatasia and hypophosphatasia in childhood]. Orthopade. 2008 Jan;37(1):31-9. doi: 10.1007/s00132-007-1181-5. PMID: 18080109.
* Millán JL, Plotkin H. Hypophosphatasia - pathophysiology and treatment. Actual osteol. 2012 Sep 1;8(3):164-182. PMID: 25254037; PMCID: PMC4171060.
* Jelin AC, O'Hare E, Blakemore K, Jelin EB, Valle D, Hoover-Fong J. Skeletal Dysplasias: Growing Therapy for Growing Bones. Front Pharmacol. 2017;8:79. doi: 10.3389/fphar.2017.00079. 2017 Mar 6. PMID: 28321190; PMCID: PMC5337493.
* 2017 Apr. PMID: 29356465.
* Qubain L, Smith P, Vij N, Belthur M. Multidisciplinary Management of Infantile Hypophosphatasia Resulting in Radiographic and Clinical Improvement: A Case Report. Cureus. 2022 May;14(5):e25426. doi: 10.7759/cureus.25426. 2022 May 28. PMID: 35769684; PMCID: PMC9235917.
* Thrailkill KM, Kalaitzoglou E, Fowlkes JL. Emerging therapies for the treatment of rare pediatric bone disorders. Front Pediatr. 2022;10:1012816. doi: 10.3389/fped.2022.1012816. 2022 Oct 11. PMID: 36304528; PMCID: PMC9592743.
* Fischer JM, Jeitler M, Blakeslee SB, Kessler C. Medical Cannabinoids as Treatment for Hypophosphatasia-Related Symptoms. Complement Med Res. 2023;30(1):84-88. doi: 10.1159/000528069. 2022 Nov 15. PMID: 36380652.
* Kimura S, Sunouchi T, Watanabe S, Hoshino Y, Hidaka N, Kato H, Takeda S, Nangaku M, Makita N, Azuma K, Kojima T, Matsubara T, Saito T, Ito N. Latent metabolic bone disease, skeletal dysplasia and other conditions related to low bone formation among 38 patients with subtrochanteric femoral fractures: a retrospective observational study. Osteoporos Int. 2024 Sep;35(9):1633-1643. doi: 10.1007/s00198-024-07168-4. 2024 Jul 1. PMID: 38951164; PMCID: PMC11364693.
* Lewiecki EM, Bilezikian JP, Clark A, Collins MT, Kado DM, Lane J, Langdahl B, McClung MR, Snyder PJ, Stein EM. Proceedings of the 2024 Santa Fe Bone Symposium: Update on the Management of Osteoporosis and Rare Bone Diseases. J Clin Densitom. 2025 Jan-Mar;28(1):101559. doi: 10.1016/j.jocd.2024.101559. 2024 Dec 28. PMID: 39826229.
* Saito F, Maeyama A, Soejima R, Koga D, Sawa M, Ikejiri Y, Yoshioka T, Murata H, Fujibayashi S, Okimoto N, Yamamoto T. Screening and patient exploration for adult hypophosphatasia in orthopedics. J Orthop Sci. 2026 Jul;31(4):949-953. doi: 10.1016/j.jos.2025.12.007. 2026 Jan 30. PMID: 41617628.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.